Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Harvard Business School
Baxter
Merck
Moodys

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,649,318

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 9,649,318 protect, and when does it expire?

Patent 9,649,318 protects VIVLODEX and is included in one NDA.

This patent has sixteen patent family members in sixteen countries.

Summary for Patent: 9,649,318
Title:Formulation of meloxicam
Abstract: Unit dosage forms of meloxicam containing either 5 mg or 10 mg of meloxicam that provide effective pain relief and have desirable pharmacokinetic properties are described. The unit dosage forms can provide pain relief when a single unit dose is administered to a patient and useful for treating pain such as osteoarthritis pain at a relatively low systemic exposure to meloxicam.
Inventor(s): Bosch; H. William (Bryn Mawr, PA)
Assignee: iCeutica Pty Ltd. (Balcatta WA, AU)
Application Number:14/974,108
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,649,318
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form;

Drugs Protected by US Patent 9,649,318

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Zyla VIVLODEX meloxicam CAPSULE;ORAL 207233-001 Oct 22, 2015 RX Yes No   Start Trial   Start Trial Y   Start Trial
Zyla VIVLODEX meloxicam CAPSULE;ORAL 207233-002 Oct 22, 2015 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,649,318

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2015274838   Start Trial
Brazil 112016027435   Start Trial
Canada 2951383   Start Trial
China 107073010   Start Trial
Eurasian Patent Organization 201692392   Start Trial
European Patent Office 3151835   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
McKinsey
AstraZeneca
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.